Integrative Network Pharmacology Study of Cordyceps militaris Compounds for Prostate Cancer Treatment

Authors

  • Sarah Cecilia Astrid Laihad Medical Education Study Program, Faculty of Medicine, Sam Ratulangi University, Manado 95115, Indonesia
  • Trina Ekawati Tallei Department of Biology, Faculty of Medicine, Sam Ratulangi University, Manado 95115, Indonesia; Department of Biology, Faculty of Mathematics and Natural Sciences, Sam Ratulangi University, Manado 95115, Indonesia
  • Lydia Estelina Naomi Tendean Department of Biology, Faculty of Medicine, Sam Ratulangi University, Manado 95115, Indonesia
  • Grace Lendawati Amelia Turalaki Department of Biology, Faculty of Medicine, Sam Ratulangi University, Manado 95115, Indonesia
  • Sylvia Ritta Marunduh Department of Physiology, Faculty of Medicine, Sam Ratulangi University, Manado 95115, Indonesia
  • Diana Shintawati Purwanto Department of Biochemistry, Faculty of Medicine, Sam Ratulangi University, Manado 95115, Indonesia
  • Billy Johnson Kepel Department of Chemistry, Faculty of Medicine, Sam Ratulangi University, Manado 95115, Indonesia
  • Abdul Hawil Abas MARBEC, Université de Montpellier, CNRS, IFREMER, IRD, INRAE 34250 Palavas-les-Flots, France

DOI:

https://doi.org/10.60084/hjas.v4i1.382

Keywords:

Molecular target prediction, Network analysis, Hub protein analysis, System pharmacology, Pathway enrichment analysis

Abstract

Prostate cancer remains one of the leading causes of cancer-related mortality in men, while adverse effects and the development of drug resistance often limit current therapeutic strategies. Natural products have gained increasing attention as potential sources of novel anticancer agents due to their multitarget properties and relatively low toxicity. Cordyceps militaris, a medicinal fungus rich in bioactive compounds, has been reported to exhibit anticancer activity; however, its compound-target interactions in prostate cancer have not been comprehensively elucidated. This study aimed to explore the interactions between C. militaris bioactive compounds and prostate cancer-associated targets using a pharmacology network-based in silico approach. A total of 50 bioactive compounds were collected from metabolite profiling studies, of which 19 compounds were selected based on high predicted TP53 expression enhancer activity (Pa ≥ 0.7) using WAY2DRUG PASS analysis. Protein targets were predicted using SwissTargetPrediction and the Similarity Ensemble Approach, and then intersected with prostate cancer-associated proteins retrieved from GEPIA2, GeneCards, and OMIM, yielding 499 overlapping targets. Protein interaction network analysis was performed using STRING and visualized in Cytoscape, enabling the identification of key hub proteins based on the applied parameters, highlighting ten key proteins, including SRC, ESR1, MAPK1, AKT1, HSP90AA1, MAPK3, HSP90AB1, EGFR, GRB2, and PRKACA, within the interaction network. Pathway enrichment analysis indicated that these targets were predominantly involved in cancer-associated signaling pathways, such as the EGFR tyrosine kinase inhibitor resistance pathway. Furthermore, the results revealed that the selected compounds interact with these key prostate cancer-associated proteins. Pharmacokinetic and toxicity evaluation predicted favorable drug-likeness and acceptable safety profiles for selected compounds. Overall, this study highlights the potential of C. militaris bioactive compounds as promising alternative for prostate cancer through multitarget modulation of clinically relevant signaling pathways. Further experimental validation is still required to confirm these findings.

Downloads

Download data is not yet available.

References

  1. Bergengren, O., Pekala, K. R., Matsoukas, K., Fainberg, J., Mungovan, S. F., Bratt, O., Bray, F., Brawley, O., Luckenbaugh, A. N., Mucci, L., Morgan, T. M., and Carlsson, S. V. (2023). 2022 Update on Prostate Cancer Epidemiology and Risk Factors—A Systematic Review, European Urology, Vol. 84, No. 2, 191–206. doi:10.1016/j.eururo.2023.04.021.
  2. Chowdry, R. P. (2024). Prostate Cancer, Screening and Prevention, ClinicalKey.
  3. Noviandy, T. R., Maulana, A., Zulfikar, T., Rusyana, A., Enitan, S. S., and Idroes, R. (2024). Explainable Artificial Intelligence in Medical Imaging: A Case Study on Enhancing Lung Cancer Detection through CT Images, Indonesian Journal of Case Reports, Vol. 2, No. 1, 6–14. doi:10.60084/ijcr.v2i1.150.
  4. Leslie, S. W., Soon-Sutton, T. L., and Skelton, W. P. (2024). Prostate Cancer, StatPearls.
  5. Lim Ng, K. (2021). The Etiology of Prostate Cancer, Prostate Cancer, Exon Publications, 17–28. doi:10.36255/exonpublications.prostatecancer.etiology.2021.
  6. Sekhoacha, M., Riet, K., Motloung, P., Gumenku, L., Adegoke, A., and Mashele, S. (2022). Prostate Cancer Review: Genetics, Diagnosis, Treatment Options, and Alternative Approaches, Molecules, Vol. 27, No. 17, 5730. doi:10.3390/molecules27175730.
  7. Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., and Jemal, A. (2024). Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries, CA: A Cancer Journal for Clinicians, Vol. 74, No. 3, 229–263. doi:10.3322/caac.21834.
  8. International Agency for Research on Cancer. (2024). IARC-Global Cancer Observatory: Indonesia. GLOBOCAN 2022 fact sheetLyon, France, International Agency for Research on Cancer.
  9. Hashem, S., Ali, T. A., Akhtar, S., Nisar, S., Sageena, G., Ali, S., Al-Mannai, S., Therachiyil, L., Mir, R., Elfaki, I., Mir, M. M., Jamal, F., Masoodi, T., Uddin, S., Singh, M., Haris, M., Macha, M., and Bhat, A. A. (2022). Targeting Cancer Signaling Pathways by Natural Products: Exploring Promising Anti-Cancer Agents, Biomedicine & Pharmacotherapy, Vol. 150, 113054. doi:10.1016/j.biopha.2022.113054.
  10. Isowa, M., Hamaguchi, R., Narui, R., Morikawa, H., Okamoto, T., and Wada, H. (2024). Exploring the Potential Use of Natural Products Together with Alkalization in Cancer Therapy, Pharmaceutics, Vol. 16, No. 6, 787. doi:10.3390/pharmaceutics16060787.
  11. Naeem, A., Hu, P., Yang, M., Zhang, J., Liu, Y., Zhu, W., and Zheng, Q. (2022). Natural Products as Anticancer Agents: Current Status and Future Perspectives, Molecules, Vol. 27, No. 23, 8367. doi:10.3390/molecules27238367.
  12. Chunarkar-Patil, P., Kaleem, M., Mishra, R., Ray, S., Ahmad, A., Verma, D., Bhayye, S., Dubey, R., Singh, H., and Kumar, S. (2024). Anticancer Drug Discovery Based on Natural Products: From Computational Approaches to Clinical Studies, Biomedicines, Vol. 12, No. 1, 201. doi:10.3390/biomedicines12010201.
  13. Noviandy, T. R., and Idroes, R. (2025). Interpretable Machine Learning QSAR Models for Classification and Screening of VEGFR-2 Inhibitors in Anticancer Drug Discovery, Malacca Pharmaceutics, Vol. 3, No. 2, 58–66. doi:10.60084/mp.v3i2.339.
  14. Huang, M., Lu, J.-J., and Ding, J. (2021). Natural Products in Cancer Therapy: Past, Present and Future, Natural Products and Bioprospecting, Vol. 11, No. 1, 5–13. doi:10.1007/s13659-020-00293-7.
  15. Utami, W. P., Tallei, T. E., Turalaki, G. L. A., Tendean, L. E. N., Kaseke, M. M., and Purwanto, D. S. (2025). Targeting Prostate Cancer with Rambutan Peel-Derived Compounds via Network Pharmacology, Malacca Pharmaceutics, Vol. 3, No. 1, 42–49. doi:10.60084/mp.v3i1.262.
  16. Maulydia, N. B., Khairan, K., Tallei, T. E., Salaswati, S., Musdalifah, A., Nabila, F. F., and Idroes, R. (2024). Exploring the Medicinal Potential of Blumea Balsamifera: Insights from Molecular Docking and Molecular Dynamics Simulations Analyses, Malacca Pharmaceutics, Vol. 2, No. 1, 33–40. doi:10.60084/mp.v2i1.168.
  17. Zhang, J., Wu, Y., Li, Y., Li, S., Liu, J., Yang, X., Xia, G., and Wang, G. (2024). Natural Products and Derivatives for Breast Cancer Treatment: From Drug Discovery to Molecular Mechanism, Phytomedicine, Vol. 129, 155600. doi:10.1016/j.phymed.2024.155600.
  18. Landi, N., Clemente, A., Pedone, P. V, Ragucci, S., and Di Maro, A. (2022). An Updated Review of Bioactive Peptides from Mushrooms in a Well-Defined Molecular Weight Range, Toxins, Vol. 14, No. 2, 84. doi:10.3390/toxins14020084.
  19. Jo, E., Jang, H.-J., Shen, L., Yang, K. E., Jang, M. S., Huh, Y. H., Yoo, H.-S., Park, J., Jang, I. S., and Park, S. J. (2020). Cordyceps Militaris Exerts Anticancer Effect on Non–Small Cell Lung Cancer by Inhibiting Hedgehog Signaling via Suppression of TCTN3, Integrative Cancer Therapies, Vol. 19, 1534735420923756. doi:10.1177/1534735420923756.
  20. Hu, J.-J., Zhao, G.-P., Tuo, Y.-L., Dai, D., Guo, D.-Z., Rao, G., Qi, Z.-X., Zhang, Z.-H., Li, Y., and Zhang, B. (2021). Morphology and Molecular Study of Three New Cordycipitoid Fungi and Its Related Species Collected from Jilin Province, Northeast China, MycoKeys, Vol. 83, 161–180. doi:10.3897/mycokeys.83.72325.
  21. Pintathong, P., Chomnunti, P., Sangthong, S., Jirarat, A., and Chaiwut, P. (2021). The Feasibility of Utilizing Cultured Cordyceps Militaris Residues in Cosmetics: Biological Activity Assessment of Their Crude Extracts, Journal of Fungi, Vol. 7, No. 11, 973. doi:10.3390/jof7110973.
  22. Lee, H. H., Lee, S., Lee, K., Shin, Y. S., Kang, H., and Cho, H. (2015). Anti-Cancer Effect of Cordyceps Militaris in Human Colorectal Carcinoma RKO Cells via Cell Cycle Arrest and Mitochondrial Apoptosis, DARU Journal of Pharmaceutical Sciences, Vol. 23, No. 1, 35. doi:10.1186/s40199-015-0117-6.
  23. Yu, G., Peng, J., Li, L., Yu, W., He, B., and Xie, B. (2024). The Role and Mechanisms of Cordycepin in Inhibiting Cancer Cells, Brazilian Journal of Medical and Biological Research, Vol. 57, e13889. doi:10.1590/1414-431x2024e13889.
  24. Lee, D., Lee, W.-Y., Jung, K., Kwon, Y., Kim, D., Hwang, G., Kim, C.-E., Lee, S., and Kang, K. (2019). The Inhibitory Effect of Cordycepin on the Proliferation of MCF-7 Breast Cancer Cells, and Its Mechanism: An Investigation Using Network Pharmacology-Based Analysis, Biomolecules, Vol. 9, No. 9, 414. doi:10.3390/biom9090414.
  25. Zhang, J., Yang, Z., Zhao, Z., and Zhang, N. (2024). Structural and Pharmacological Insights into Cordycepin for Neoplasms and Metabolic Disorders, Frontiers in Pharmacology, Vol. 15, 1367820. doi:10.3389/fphar.2024.1367820.
  26. Li, F., Ma, Y., Hua, W., Liu, Y., Li, L., and Lu, Z. (2022). Cordyceps Militaris Polysaccharide Exerted Anticancer Effect via Activating the Endogenous Apoptosis Pathway, Pharmacognosy Magazine, Vol. 18, No. 79, 669–674.
  27. Lee, J.-D. (2012). Inhibition of Migration and Invasion of LNCaP Human Prostate Carcinoma Cells by Cordycepin through Inactivation of Akt, International Journal of Oncology, Vol. 40, No. 5, 1697–1704. doi:10.3892/ijo.2012.1332.
  28. Lee, H. H., Park, C., Jeong, J., Kim, M. J., Seo, M. J., Kang, B. W., Park, J. U., Kim, G., Choi, B. T., Choi, Y. H., and Jeong, Y. K. (2013). Apoptosis Induction of Human Prostate Carcinoma Cells by Cordycepin through Reactive Oxygen Species-Mediated Mitochondrial Death Pathway, International Journal of Oncology, Vol. 42, No. 3, 1036–1044. doi:10.3892/ijo.2013.1762.
  29. Kusama, K., Suzuki, T., Motohashi, R., Nobusawa, T., Ota, K., Azumi, M., Yoshie, M., Miyaoka, H., and Tamura, K. (2022). Cordyceps Militaris Extract and the Main Component, Cordycepin, Modulate the Functions of Prostate Cancer Cells Partially Through the Adenosine A1 Receptor, Natural Product Communications, Vol. 17, No. 10. doi:10.1177/1934578X221130859.
  30. Liu, S., and Yu, Y.-W. (2025). Network Pharmacology: Changes the Treatment Mode of ‘One Disease-One Target’ in Cancer Treatment, World Journal of Gastrointestinal Oncology, Vol. 17, No. 1. doi:10.4251/wjgo.v17.i1.101581.
  31. Huang, H., Li, X., Wu, W., Liu, C., Shao, Y., Wu, X., and Fu, J. (2024). Cordycepin Enhances the Therapeutic Efficacy of Doxorubicin in Treating Triple-Negative Breast Cancer, International Journal of Molecular Sciences, Vol. 25, No. 13, 7077. doi:10.3390/ijms25137077.
  32. Chen, Y., Wang, P., Zhang, M., Yang, H., and Liang, B. (2026). Mechanism Analysis of the Effect of Cordycepin on Colorectal Cancer via Network Pharmacology and Experiment, Combinatorial Chemistry & High Throughput Screening, Vol. 29, No. 3, 411–422. doi:10.2174/0113862073322771241119101357.
  33. Zhai, Y., Liu, L., Zhang, F., Chen, X., Wang, H., Zhou, J., Chai, K., Liu, J., Lei, H., Lu, P., Guo, M., Guo, J., and Wu, J. (2025). Network Pharmacology: A Crucial Approach in Traditional Chinese Medicine Research, Chinese Medicine, Vol. 20, No. 1, 8. doi:10.1186/s13020-024-01056-z.
  34. Prasetyorini, B. E., Kusumawardani, A., Fitriani, F., Rachman, P. O., Amelinda, N., and Ramadhani, A. (2022). Analisis In Silico Senyawa Aktif Batang Kayu Bajakah (Spatholobus Littoralis Hassk) Sebagai Terapi Psoriasis, Herb-Medicine Journal, Vol. 5, No. 1, 26. doi:10.30595/hmj.v5i2.12744.
  35. Ofner, H., Kramer, G., Shariat, S. F., and Hassler, M. R. (2025). TP53 Deficiency in the Natural History of Prostate Cancer, Cancers, Vol. 17, No. 4, 645. doi:10.3390/cancers17040645.
  36. Wang, X., and Sun, Q. (2017). TP53 Mutations, Expression and Interaction Networks in Human Cancers, Oncotarget, Vol. 8, No. 1, 624–643. doi:10.18632/oncotarget.13483.
  37. Kumar, V., Abbas, A. K., and Aster, J. C. (2012). Robbins Basic Pathology (9th ed.), Elsevier Health Sciences.
  38. Snoek, R., Cheng, H., Margiotti, K., Wafa, L. A., Wong, C. A., Wong, E. C., Fazli, L., Nelson, C. C., Gleave, M. E., and Rennie, P. S. (2009). In Vivo Knockdown of the Androgen Receptor Results in Growth Inhibition and Regression of Well-Established, Castration-Resistant Prostate Tumors, Clinical Cancer Research, Vol. 15, No. 1, 39–47. doi:10.1158/1078-0432.CCR-08-1726.
  39. Fatimawali, Tallei, T. E., Kepel, B. J., Bodhi, W., Manampiring, A. E., and Nainu, F. (2023). Molecular Insight into the Pharmacological Potential of Clerodendrum Minahassae Leaf Extract for Type-2 Diabetes Management Using the Network Pharmacology Approach, Medicina, Vol. 59, No. 11, 1899. doi:10.3390/medicina59111899.
  40. Shamsol Azman, A. N. S., Tan, J. J., Abdullah, M. N. H., Bahari, H., Lim, V., and Yong, Y. K. (2023). Network Pharmacology and Molecular Docking Analysis of Active Compounds in Tualang Honey against Atherosclerosis, Foods, Vol. 12, No. 9, 1779. doi:10.3390/foods12091779.
  41. Thakur, S., Piplani, M., Goyal, P., and Bhateja, P. (2024). Metabolite Profiling and Morphological Screening of C. Militaris Fruiting Bodies Extracts Using UHPLC-QTOF-IMS and GC-MS Analysis, ASEAN Journal of Scientific and Technological Reports, Vol. 27, No. 6, e254493. doi:10.55164/ajstr.v27i6.254493.
  42. Oh, J., Yoon, D.-H., Shrestha, B., Choi, H.-K., and Sung, G.-H. (2019). Metabolomic Profiling Reveals Enrichment of Cordycepin in Senescence Process of Cordyceps Militaris Fruit Bodies, Journal of Microbiology, Vol. 57, No. 1, 54–63. doi:10.1007/s12275-019-8486-z.
  43. Belli, S., Esposito, D., Servetto, A., Pesapane, A., Formisano, L., and Bianco, R. (2020, June 7). C-Src and EGFR Inhibition in Molecular Cancer Therapy: What Else Can We Improve?, Cancers, 1–16. doi:10.3390/cancers12061489.
  44. Li, J., Wang, X., Xue, L., and He, Q. (2024). Exploring the Therapeutic Mechanism of Curcumin in Prostate Cancer Using Network Pharmacology and Molecular Docking, Heliyon, Vol. 10, No. 12, e33103. doi:10.1016/j.heliyon.2024.e33103.
  45. Varkaris, A., Katsiampoura, A. D., Araujo, J. C., Gallick, G. E., and Corn, P. G. (2014). Src Signaling Pathways in Prostate Cancer, Cancer and Metastasis Reviews, Vol. 33, Nos. 2–3, 595–606. doi:10.1007/s10555-013-9481-1.
  46. Belluti, S., Imbriano, C., and Casarini, L. (2023). Nuclear Estrogen Receptors in Prostate Cancer: From Genes to Function, Cancers, Vol. 15, No. 18, 4653. doi:10.3390/cancers15184653.
  47. Wang, Y., Guo, Z., Tian, Y., Cong, L., Zheng, Y., Wu, Z., Shan, G., Xia, Y., Zhu, Y., Li, X., and Song, Y. (2023). MAPK1 Promotes the Metastasis and Invasion of Gastric Cancer as a Bidirectional Transcription Factor, BMC Cancer, Vol. 23, No. 1, 959. doi:10.1186/s12885-023-11480-3.
  48. Sigismund, S., Avanzato, D., and Lanzetti, L. (2018). Emerging Functions of the EGFR in Cancer, Molecular Oncology, Vol. 12, No. 1, 3–20. doi:10.1002/1878-0261.12155.
  49. Lin, S.-R., Yeh, H.-L., and Liu, Y.-N. (2021). Interplay of Epidermal Growth Factor Receptor and Signal Transducer and Activator of Transcription 3 in Prostate Cancer: Beyond Androgen Receptor Transactivation, Cancers, Vol. 13, No. 14, 3452. doi:10.3390/cancers13143452.
  50. Cargnello, M., and Roux, P. P. (2011). Activation and Function of the MAPKs and Their Substrates, the MAPK-Activated Protein Kinases, Microbiology and Molecular Biology Reviews, Vol. 75, No. 1, 50–83. doi:10.1128/MMBR.00031-10.
  51. Pelaz, S. G., and Tabernero, A. (2022). Src: Coordinating Metabolism in Cancer, Oncogene, Vol. 41, No. 45, 4917–4928. doi:10.1038/s41388-022-02487-4.
  52. Martin-Vega, A., and Cobb, M. H. (2023). Navigating the ERK1/2 MAPK Cascade, Biomolecules, Vol. 13, No. 10, 1555. doi:10.3390/biom13101555.
  53. Sah, V. K., Singh, A. K., Kumar, A., Prajapati, V., Kalsi, A. S., Khalilullah, H., Jaremko, M., Emwas, A.-H., Verma, A., and Kumar, P. (2025). Advances in ERK1/2 Inhibition: A Medicinal Chemistry Perspective on Structure and Regulation, Journal of Enzyme Inhibition and Medicinal Chemistry, Vol. 40, No. 1, 2555510. doi:10.1080/14756366.2025.2555510.
  54. Jefferi, N. E. S., Shamhari, A. ‘Afifah, Noor Azhar, N. K. Z., Shin, J. G. Y., Kharir, N. A. M., Azhar, M. A., Hamid, Z. A., Budin, S. B., and Taib, I. S. (2023). The Role of ERα and ERβ in Castration-Resistant Prostate Cancer and Current Therapeutic Approaches, Biomedicines, Vol. 11, No. 3, 826. doi:10.3390/biomedicines11030826.

Downloads

Published

2026-03-30

How to Cite

Laihad, S. C. A., Tallei , T. E., Tendean , L. E. N., Turalaki, G. L. A., Marunduh, S. R., Purwanto , D. S., Kepel, B. J. and Abas, A. H. (2026) “Integrative Network Pharmacology Study of Cordyceps militaris Compounds for Prostate Cancer Treatment”, Heca Journal of Applied Sciences, 4(1), pp. 70–87. doi: 10.60084/hjas.v4i1.382.

Issue

Vol. 4 No. 1 (2026): March 2026

Section

Articles

License

Copyright (c) 2026 Sarah Cecilia Astrid Laihad, Trina Ekawati Tallei , Lydia Estelina Naomi Tendean , Grace Lendawati Amelia Turalaki, Sylvia Ritta Marunduh, Diana Shintawati Purwanto , Billy Johnson Kepel, Abdul Hawil Abas

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.